Compare Amylx Pharmaceuticals Inc (AMLX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Clear Secure Inc trades at $48.23 (market cap $5.28B). The key difference: Clear Secure Inc is far larger — about 2.1× Amylx Pharmaceuticals Inc's market cap, and Clear Secure Inc pays a 1.12% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | YOU | |
|---|---|---|
Market Cap | $2.53B | $5.28B |
Sector | Health | Technology |
52-Week High | $24.19 | $62.36 |
52-Week Low | $7.82 | $29.61 |
Enterprise Value | $2.28B | $4.43B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Clear Secure (YOU) trades at $51.29, down 3.26% in 24 hours, with a bearish technical signal but strong fundamentals including 66.66% gross margins and 90.29% ROE. Recent Q2 2026 earnings beat estimates with EPS of $0.49 versus $0.40 expected, driven by double-digit revenue growth and record free cash flow. The company launched corporate memberships to expand its identity platform, enhancing business travel offerings.
Outlook is mixed: robust profitability and growth initiatives support upside, but high valuation (P/E 34.6) and technical weakness near support at $50 pose risks. Analyst consensus is balanced with 44% buy ratings, yet insider selling and competitive pressures require caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
